The Company is a leading medical genetics testing company.
The Company had established itself as a well known testing company with a specific expertise in neonatal testing. The Company was approached by a larger testing company that was interested in pursuing an acquisition. Trestle was asked to help the Company evaluate the unsolicited offer and explore other alternatives that might be available to the Company.
After reviewing a number of potential alternatives, the Company settled on an alternative transaction that was more attractive than the original unsolicited offer. The Company was sold to a division of a publicly traded corporation in a cash deal that achieved maximum liquidity for the owners.